Eli Lilly and Company (LLY)vsSarepta Therapeutics Inc (SRPT)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
SRPT
Sarepta Therapeutics Inc
$15.75
-5.46%
HEALTHCARE · Cap: $1.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 3208% more annual revenue ($72.25B vs $2.18B). LLY leads profitability with a 35.0% profit margin vs 3.0%. LLY appears more attractively valued with a PEG of 1.45. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SRPT
Buy59
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 49.0%
Earnings expanding 2664.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Smaller company, higher risk/reward
ROE of 4.3% — below average capital efficiency
3.0% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SRPT
The strongest argument for SRPT centers on Price/Book, Operating Margin, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SRPT
The primary concerns for SRPT are Market Cap, Return on Equity, Profit Margin. A P/E of 51.1x leaves little room for execution misses. Thin 3.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while SRPT is a value play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 59/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sarepta Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?